Pemetrexed: Difference between revisions
m Protected "Pemetrexed": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 23: | Line 23: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 44: | Line 44: | ||
*[http://www.cancer.gov/cancertopics/druginfo/pemetrexeddisodium NCI Drug Information Summary on Pemetrexed Disodium] | *[http://www.cancer.gov/cancertopics/druginfo/pemetrexeddisodium NCI Drug Information Summary on Pemetrexed Disodium] | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
[[Category:Dihydrofolate reductase inhibitors]] | [[Category:Dihydrofolate reductase inhibitors]] | ||
Revision as of 14:52, 20 August 2012
| File:Pemetrexed.svg | |
| Clinical data | |
|---|---|
| [[Regulation of therapeutic goods |Template:Engvar data]] |
|
| Pregnancy category |
|
| Routes of administration | IV |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | 81% |
| Metabolism | Negligible |
| Elimination half-life | 3.5 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H21N5O6 |
| Molar mass | 427.411 g/mol |
|
WikiDoc Resources for Pemetrexed |
|
Articles |
|---|
|
Most recent articles on Pemetrexed |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Pemetrexed at Clinical Trials.gov Clinical Trials on Pemetrexed at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pemetrexed
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pemetrexed Discussion groups on Pemetrexed Patient Handouts on Pemetrexed Directions to Hospitals Treating Pemetrexed Risk calculators and risk factors for Pemetrexed
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pemetrexed |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Pemetrexed (brand name Alimta®) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
History
The molecular structure of pemetrexed was developed by Edward C. Taylor at Princeton University and clinically developed by Indianapolis based drug maker, Eli Lilly and Company.
Mechanism of action
Pemetrexed is chemically similar to folic acid and is in the class of chemotherapy drugs called folate antimetabolites. It works by inhibiting three enzymes used in purine and pyrimidine synthesis—thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyl transferase (GARFT). By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.
Clinical use
In February 2004, the Food and Drug Administration approved pemetrexed for treatment of malignant pleural mesothelioma, a type of tumor of the lining of the lung, in combination with cisplatin. In July 2004, the FDA granted approval as a second-line agent for the treatment of non-small cell lung cancer. Trials are currently testing it against esophagus and other cancers.
Patients are required to be on folic acid and vitamin B12 supplementation when they are on pemetrexed therapy. (In clinical trials for mesothelioma, folic acid and B12 supplementation reduced the frequency of adverse events.) It is also recommended for patients to be on a steroid (e.g. dexamethasone 4mg twice daily) on the day prior, day of, and day after pemetrexed infusion to avoid skin rashes.
External links
- Alimta website
- Alimta / Pemetrexed Virtual Cancer Centre
- NCI Drug Information Summary on Pemetrexed Disodium
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents
- Dihydrofolate reductase inhibitors
- Lilly